Biofrontera Says Sun Pharmaceutical Alleging Breach of Contract In Lawsuit
By Ben Glickman
Biofrontera is being sued by Sun Pharmaceutical, which alleges the company improperly promoted its Ameluz product.
The Woburn, Mass.-based dermatology-focused biopharmaceutical company said in a Tuesday regulatory filing it had been served the complaint, which was filed by Sun and connected companies on Sept. 13.
Biofrontera denies the claims and "intends to defend these matters vigorously."
The lawsuit alleges Biofrontera committed breach of contract and unfair trade practices and violated the Lanham Act, a trademark law.
"All claims stem from allegations that Biofrontera has promoted its Ameluz product in a manner that is inconsistent with its approved FDA labeling," Biofrontera said in the filing.
The case will be heard in the U.S. District Court for the District of New Jersey.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
October 03, 2023 18:28 ET (22:28 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?
-
Home Depot Earnings: Macro Factors Pinch Demand, but Long-Term Outlook Intact
-
Tariffs On Chinese EVs Offer US Automakers a Chance to Capture Demand
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued
-
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?